Compare ADTN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | CDNA |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1996 | 2007 |
| Metric | ADTN | CDNA |
|---|---|---|
| Price | $15.42 | $25.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $15.50 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.6M | 718.0K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $1,083,807,000.00 | $48,324,000.00 |
| Revenue This Year | $11.09 | $16.01 |
| Revenue Next Year | $8.47 | $11.31 |
| P/E Ratio | ★ N/A | $469.00 |
| Revenue Growth | 17.46 | ★ 18.93 |
| 52 Week Low | $7.11 | $10.96 |
| 52 Week High | $19.98 | $24.85 |
| Indicator | ADTN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 68.35 |
| Support Level | $14.13 | $14.59 |
| Resistance Level | $16.28 | N/A |
| Average True Range (ATR) | 1.12 | 1.23 |
| MACD | -0.17 | 0.15 |
| Stochastic Oscillator | 29.58 | 98.65 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.